Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 484

1.

Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.

Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT.

JAMA Neurol. 2015 Oct;72(10):1170-4. doi: 10.1001/jamaneurol.2015.1444.

2.

Development of generalized disease at 2 years in patients with ocular myasthenia gravis.

Kupersmith MJ, Latkany R, Homel P.

Arch Neurol. 2003 Feb;60(2):243-8.

PMID:
12580710
3.

Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.

Gunji K, Skolnick C, Bednarczuk T, Benes S, Ackrell BA, Cochran B, Kennerdell JS, Wall JR.

Clin Immunol Immunopathol. 1998 Jun;87(3):276-81.

PMID:
9646837
4.

Factors affecting outcome in ocular myasthenia gravis.

Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G.

Int J Neurosci. 2018 Jan;128(1):15-24. doi: 10.1080/00207454.2017.1344237. Epub 2017 Jul 17.

PMID:
28625092
5.

Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis.

Shi QG, Wang ZH, Ma XW, Zhang DQ, Yang CS, Shi FD, Yang L.

Neurosci Bull. 2012 Oct;28(5):469-74. doi: 10.1007/s12264-012-1256-0. Epub 2012 Jul 4.

6.

Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients.

Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK, Park KS, Park KJ, Sung JJ, Sohn EH, Lee YB, Jeong D, Joo IS, Choi BO, Choi YC; Korean Research Group for Neuromuscular Diseases.

J Neurol Sci. 2008 Oct 15;273(1-2):10-4. doi: 10.1016/j.jns.2008.05.023. Epub 2008 Jul 3.

PMID:
18602121
7.

Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.

Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, Dimachkie M.

J Clin Neuromuscul Dis. 2011 Sep;13(1):46-52. doi: 10.1097/CND.0b013e31821c5634.

PMID:
22361625
8.

Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.

Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, Hilton-Jones D, Morgan BP, Vincent A.

Arch Neurol. 2012 Aug;69(8):994-1001. doi: 10.1001/archneurol.2012.437.

PMID:
22689047
9.

Antibody profile may predict outcome in ocular myasthenia gravis.

Galassi G, Mazzoli M, Ariatti A, Kaleci S, Valzania F, Nichelli PF.

Acta Neurol Belg. 2018 Sep;118(3):435-443. doi: 10.1007/s13760-018-0943-7. Epub 2018 Jun 1.

PMID:
29858757
10.

Prognosis of Ocular Myasthenia Gravis in an Argentinian Population.

Aguirre F, Villa AM.

Eur Neurol. 2018;79(3-4):113-117. doi: 10.1159/000487132. Epub 2018 Feb 9.

PMID:
29428956
11.

Complete stable remission and autoantibody specificity in myasthenia gravis.

Baggi F, Andreetta F, Maggi L, Confalonieri P, Morandi L, Salerno F, Bernasconi P, Montomoli C, Barberis M, Mantegazza R, Antozzi C.

Neurology. 2013 Jan 8;80(2):188-95. doi: 10.1212/WNL.0b013e31827b907b. Epub 2012 Dec 19.

PMID:
23255823
12.

Some clinico-immunological aspects in patients with ocular myasthenia gravis associated with inflammatory bowel disease.

Cojocaru IM, Cojocaru M, Tănăsescu R, Burcin C, Atanasiu AN, Mitu AC, Iliescu I, Dumitrescu L.

Rom J Intern Med. 2008;46(2):165-8.

PMID:
19284089
13.

T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis.

Wang ZY, Diethelm-Okita B, Okita DK, Kaminski HJ, Howard JF, Conti-Fine BM.

J Neuroimmunol. 2000 Aug 1;108(1-2):29-39.

PMID:
10900334
14.

Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia gravis.

Pasutharnchat N, Wacharapluesadee S, Hemachudha T.

J Med Assoc Thai. 2012 Mar;95(3):313-9.

PMID:
22550827
15.
16.

Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis.

Aurangzeb S, Tariq M, Irshad M, Badshah M, Khan RS.

J Pak Med Assoc. 2009 May;59(5):289-92.

17.

Acetylcholine receptor antibody in Thai generalized myasthenia gravis patients.

Jitpimolmard S, Taimkao S, Chotmongkol V, Sawanyawisuth K, Vincent A, Newsom-Davis J.

J Med Assoc Thai. 2006 Jan;89(1):68-71.

PMID:
16583584
18.

[Ocular myasthenia gravis: diagnostic aspects and evolution].

de Entrambasaguas M, López-Bernabé R, López-Alemany M.

Rev Neurol. 2007 Apr 1-15;44(7):397-403. Spanish.

19.

Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.

Cortés-Vicente E, Gallardo E, Martínez MÁ, Díaz-Manera J, Querol L, Rojas-García R, Illa I.

JAMA Neurol. 2016 Sep 1;73(9):1099-104. doi: 10.1001/jamaneurol.2016.2032.

PMID:
27379450

Supplemental Content

Support Center